A 'Health Tech' That Accepts February 31st Birthdays, PBMs Use Selective Math to Prove Everyone Loves Them, and Obesity Meds Enter Their Universal Statin Era

Hey all, 

Happy Thursday! The traditional medical system has become so prohibitively expensive and culturally alienating that we’ve paved a gold-plated runway for "business-in-a-box" schemes to masquerade as clinical care. As AI tools lower the barrier to entry, expect a flood of companies following the MEDVi blueprint, where the "clinical model" is actually just a high-speed marketing funnel built entirely on the back of consumer mistrust in the establishment. My biggest peeve were sites like Medvi peddling "Tirzepatide pills" to desperate patients while Eli Lilly was spending billions to develop an entirely new molecule for its oral GLP-1—a move they didn't make "for fun," but because a Tirzepatide pill doesn't work.

Enjoy the rundown! 

Jacob Brody (Co-Founder & CEO, ZorroRX)

[The Health API Guy] The MEDVi Files: Lawsuits, Affiliate Marketing, and the GLP-1 Infrastructure

A series of federal and state lawsuits against MEDVi reveal a highly coordinated customer acquisition machine that utilized aggressive affiliate marketing and automated outreach to fuel a $1.8 billion GLP-1 telehealth operation. These filings suggest that MEDVi acted as a central hub in a broader "business-in-a-box" model powered by OpenLoop’s infrastructure, highlighting a significant shift in the GLP-1 landscape where the legal accountability of "middleware" platforms is increasingly being tested by both consumers and pharmaceutical giants. When a platform’s clinical rigor is so advanced that it accepts "February 31st" as a legitimate birthday, it becomes abundantly clear that MEDVi isn’t actually running a healthcare company, but rather a high-speed marketing funnel where the only vital sign that truly matters is a valid credit card.

Full Article

[Brian Reid's Cost Curve] PCMA’s Transparency Narrative and Employer Satisfaction Survey Analysis

PCMA has recently shifted toward an aggressive "overcommunication" strategy, highlighting a survey that claims high employer satisfaction with PBM transparency despite earlier lobbying efforts against reform. This data is viewed with skepticism as it contradicts independent findings of widespread employer frustration and utilizes a sample that significantly underrepresents the "Big 3" PBMs. Apparently, if you simply ignore the three massive PBMs that actually handle everyone’s claims, the industry looks like a customer service paradise—a convenient "oversight" that allows for a relentless barrage of blog posts celebrating a reality that doesn't actually exist.

Full Article

[Drugstore Cowboy] The Next Phase of GLP-1s Has Arrived.

The FDA’s lightning-fast approval of Eli Lilly’s Foundayo marks the official end of the "refrigerated needle" era by introducing a daily pill that functions like normal medicine without the baggage of strict fasting or water-intake rituals. While critics might obsess over its slightly lower weight-loss percentage, the drug’s true power lies in its ability to eliminate the psychological and physical friction that has kept millions of eligible patients on the sidelines. This shift signals that GLP-1s are transitioning from a boutique, high-maintenance treatment into a mass-market health staple comparable to the widespread adoption of statins. Since it turns out most people find the "stabbing yourself and fasting" combo to be a bit of a lifestyle buzzkill, we’re now about ten minutes away from these pills being so universal that staying "natural" will feel like choosing to live in a cave without Wi-Fi just to keep the "authentic" human experience of struggling alive.

Full Article